-
127
-
94
-
91
-
45
-
45
Vol. 2 No. 5: New Drugs in Hematology, Bologna, Italy 5-7 October 2008
Published:
2009-06-23
Articles
-
Myelodysplastic syndromes
Published: June 23, 2009195PDF: 107 -
Organ damage and iron overload
Published: June 23, 2009276PDF: 1400 -
Progress in the management of iron overload in erytrocyte disorders
Published: June 23, 2009211PDF: 1691 -
Ph positive-leukemias
Published: June 23, 2009163PDF: 161 -
Thyrosin kinase inhibitors: nilotinib
Published: June 23, 2009349PDF: 430 -
New drugs to overcome meccanisms of resistance in Ph+ leukemia: bosutinib
Published: June 23, 2009208PDF: 208 -
Peripheral T-cell lymphomas
Published: June 23, 2009241PDF: 571 -
Histone deacetylase inhibitors: SAHA (Vorinostat). A treatment option for advanced cutaneous T-cell lymphoma
Published: June 23, 2009229PDF: 2242 -
Chronic lymphocytic leukemia
Published: June 23, 2009189PDF: 2487 -
Monoclonal antibodies (update): CD20, rituximab
Published: June 23, 2009182PDF: 120 -
90Y-ibritumumab tiuxetan (Zevalin)
Published: June 23, 2009218PDF: 351 -
Update of alemtuzumab in the treatment of chronic lymphocytic leukaemia
Published: June 23, 2009177PDF: 212 -
Immunotherapy with epratuzumab in B-cell non-Hodgkin’s lymphoma
Published: June 23, 2009146PDF: 354 -
New agents for the treatment of acute myeloid leukemia: gemtuzumab ozogamicin
Published: June 23, 2009155PDF: 552 -
Update on galiximab: anti-CD80 monoclonal antibody
Published: June 23, 2009207PDF: 243 -
CMC-544 (inotuzumab ozogamicin): A CD22-targeted immunoconjugate of calicheamicin
Published: June 23, 2009621PDF: 2402 -
Zanolimumab (HuMax-CD4®), a fully human monoclonal antibody in clinical development for cutaneous T-cell lymphoma
Published: June 23, 2009260PDF: 328 -
Monoclonal antibodies (novel): humax-CD20, ofatumumab
Published: June 23, 2009174PDF: 203 -
Lumiliximab in chronic lymphocytic leukemia
Published: June 23, 2009172PDF: 435 -
Bevacizumab as an anti-VEGF strategy in lymphoma
Published: June 23, 2009270PDF: 181 -
Individualizing therapy for the hematologic malignancies: the stuff of genes and dreams
Published: June 23, 2009181PDF: 269 -
Aurora kinase inhibitor: AS703569
Published: June 23, 2009206PDF: 279 -
From cell biology to therapy: lenalidomide in untreated multiple myeloma
Published: June 23, 2009177PDF: 220 -
Pha-739358: a pan-aurora kinase inhibitor
Published: June 23, 2009224Untitled (): 0PDF: 423 -
From cell biology to therapy: lenalidomide in relapsed/refractory multiple myeloma
Published: June 23, 2009164PDF: 272 -
From cell biology to therapy: forodesine
Published: June 23, 2009367PDF: 730 -
Flavopiridol (alvocidib) in chronic lymphocytic leukemia
Published: June 23, 2009310PDF: 789 -
mTOR inhibitors for the treatment of lymphoma
Published: June 23, 2009185PDF: 320 -
-
Proteasome inhibitors: bortezomib in multiple myeloma
Published: June 23, 2009163PDF: 200 -
Bortezomib in lymphomas
Published: June 23, 2009169PDF: 147 -
Novel proteasome inhibitors
Published: June 23, 2009193PDF: 320 -
Decitabine in myeloid malignancies
Published: June 23, 2009167PDF: 772 -
J-L. Harousseau Tipifarnib in hematologic malignancies
Published: June 23, 2009152PDF: 230 -
Is there a role for immunotherapy in Hodgkin’s disease?
Published: June 23, 2009145PDF: 551 -
New agents for the treatment of acute myeloid leukemia: midostaurin
Published: June 23, 2009213PDF: 874 -
Lestaurtinib as a FLT3 inhibitor
Published: June 23, 2009148PDF: 165Untitled (): 0